364 results on '"O'Reilly, Steven"'
Search Results
2. Emerging therapeutic targets in systemic sclerosis
3. Epigenetics as a versatile regulator of fibrosis
4. S100A4 a classical DAMP as a therapeutic target in fibrosis
5. The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.
6. Gremlin: a complex molecule regulating wound healing and fibrosis
7. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential
8. Emerging therapeutic targets in systemic sclerosis.
9. Keeping time on liver fibrosis
10. Metabolic perturbations in systemic sclerosis
11. The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target
12. Interleukin-11 and its eminent role in tissue fibrosis: A possible therapeutic target
13. Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis
14. Functional consequences of cross-linked actin networks in bovine trabecular meshwork cells
15. Pulmonary fibrosis in COVID19: mechanisms, consequences, and targets
16. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
17. Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.
18. Elevated interleukin‐11 in systemic sclerosis and role in disease pathogenesis.
19. Targeting the TLR4–MD2 axis in systemic sclerosis
20. At the crossroads of inflammation and fibrosis: epiregulin
21. List of Contributors
22. Systemic Sclerosis and Epigenetics
23. Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: advances and opportunities for therapy
24. Innate Immunity in Systemic Sclerosis
25. Interleukin-36α is elevated in diffuse systemic sclerosis and may potentiate fibrosis
26. Toll-like receptor triggering in systemic sclerosis: time to target
27. The c-Rel Subunit of NF-κB Regulates Epidermal Homeostasis and Promotes Skin Fibrosis in Mice
28. 04.22 Circadian clock and fibrosis
29. Toll-like receptor triggering in systemic sclerosis: time to target.
30. Role of innate immune system in systemic sclerosis
31. Interleukin-6, its role in fibrosing conditions
32. Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis
33. Metabolic perturbations in systemic sclerosis
34. Keeping time on liver fibrosis
35. The Cell-Permeable Derivative of the Immunoregulatory Metabolite Itaconate, 4-Octyl Itaconate, Is Anti-Fibrotic in Systemic Sclerosis
36. Circulating Gremlin-1 is elevated in systemic sclerosis patients
37. The emerging role of metabolism in fibrosis
38. Multi-disciplinary practices : an assorted mix of businesses.
39. Multidisciplinary practices: an assorted mix of businesses
40. Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis
41. Cross-linked actin networks (CLANS) are present in lamina cribrosa cells
42. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts
43. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis
44. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis
45. microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis
46. Therapeutic targeting of T cells in systemic sclerosis
47. Metabolic perturbations in systemic sclerosis.
48. T cells in systemic sclerosis: a reappraisal
49. Wnt antagonist DKK‐1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a‐3p
50. cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.